A prospective, single-arm, open-label dose-exploration and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of LCAR-F33S in patients with relapsed/refractory multiple myeloma(Investigator-initiated Study).
This trial phase represents an early or specialized stage of clinical development.
Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.
Legend Biotech (LEGN) is the sponsoring company for this trial. BiotechSign currently grades this company F (23/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.